PDF herunterladen
CC BY 4.0 · Thromb Haemost 2023; 123(03): 317-325
DOI: 10.1055/a-1983-0594
Coagulation and Fibrinolysis

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Laura H. Bukkems 
1   Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, Noord-Holland, The Netherlands
,
Olav Versloot 
2   Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands
3   Department of Physiotherapy, Institute of Movement Studies, University of Applied Science, Utrecht, The Netherlands
,
Marjon H. Cnossen
4   Department of Pediatric Hematology and Oncology, Erasmus University Medical Center - Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands
,
Siv Jönsson 
5   Department of Pharmacy, Uppsala University, Uppsala, Sweden
,
Mats O. Karlsson
5   Department of Pharmacy, Uppsala University, Uppsala, Sweden
,
Ron A.A. Mathôt
1   Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, Noord-Holland, The Netherlands
,
Kathelijn Fischer
2   Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands
› Institutsangaben Funding This study was funded by Bayer. L.H.B is funded by the OPTI-CLOT/To-WiN studies and the SYMPHONY consortium. The SYMPHONY consortium aims to orchestrate personalized treatment in people with bleeding disorders, and is a unique collaboration between patients, health care professionals, and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. It aims to identify the best treatment choice for each individual based on bleeding phenotype. In order to achieve this goal, workpackages have been organized according to three themes, e.g. Diagnostics (workpackage 3 and 4); Treatment (workpackages 5–9), and Fundamental Research (workpackages 10–12). This research received funding from the Netherlands Organization for Scientific Research (NWO) in the framework of the NWA-ORC Call grant agreement NWA.1160.18.038. Principal investigator: Dr. M. H. Cnossen; project coordinator: Dr. S. H. Reitsma.
Beneficiaries of the SYMPHONY consortium: Erasmus University Medical Center-Sophia Children's Hospital, project leadership and coordination; Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical Centers; University Medical Center Groningen; University Medical Center Utrecht; Leiden University Medical Center; Radboud University Medical Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring B.V., and Swedish Orphan Biovitrum (Belgium) BVBA/SPRL.
› Weitere Informationen
   Lizenzen und Reprints


Abstract

Background Little is known on how sports participation affects bleeding risk in hemophilia. This study aimed to examine associations between sports participation, factor VIII (FVIII) levels and bleeding in persons with hemophilia A.

Methods In this observational, prospective, single-center study, persons with hemophilia A who regularly participated in sports were followed for 12 months. The associations of patient characteristics, FVIII levels, and type/frequency of sports participation with bleeding were analyzed by repeated time-to-event modelling.

Results One hundred and twelve persons (median age: 24 years [interquartile range:16–34], 49% severe, 49% on prophylaxis) were included. During follow-up, 70 bleeds of which 20 sports-induced were observed. FVIII levels were inversely correlated with the bleeding hazard; a 50% reduction of the baseline bleeding hazard was observed at FVIII levels of 3.1 and a 90% reduction at 28.0 IU/dL. The bleeding hazard did not correlate with sports participation. In addition, severe hemophilia, prestudy annual bleeding rate, and presence of arthropathy showed a positive association with the bleeding hazard.

Conclusion This analysis showed that FVIII levels were an important determinant of the bleeding hazard, but sports participation was not. This observation most likely reflects the presence of adequate FVIII levels during sports participation in our study. Persons with severe hemophilia A exhibited a higher bleeding hazard at a similar FVIII levels than nonsevere, suggesting that the time spent at lower FVIII levels impacts overall bleeding hazard. These data may be used to counsel persons with hemophilia regarding sports participation and the necessity of adequate prophylaxis.

Keywords

bleeding - hemophilia A - prophylaxis - repeated time-to-event - sports

Supplementary Material



Publikationsverlauf

Eingereicht: 04. Juli 2022

Angenommen: 20. Oktober 2022

Accepted Manuscript online:
19. November 2022

Artikel online veröffentlicht:
31. Dezember 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mahlangu J, Oldenburg J, Paz-Priel I. et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med 2018; 379 (09) 811-822
    CrossrefPubMedGoogle Scholar
  • 2 McLain LG, Heldrich FT. Hemophilia and sports. Phys Sportsmed 1990; 18 (11) 73-80
    CrossrefPubMedGoogle Scholar
  • 3 Koch B, Galioto Jr FM, Kelleher J, Goldstein D. Physical fitness in children with hemophilia. Arch Phys Med Rehabil 1984; 65 (06) 324-326
    PubMedGoogle Scholar
  • 4 Falk B, Portal S, Tiktinsky R, Weinstein Y, Constantini N, Martinowitz U. Anaerobic power and muscle strength in young hemophilia patients. Med Sci Sports Exerc 2000; 32 (01) 52-57
    CrossrefPubMedGoogle Scholar
  • 5 Hilberg T, Herbsleb M, Gabriel HHW, Jeschke D, Schramm W. Proprioception and isometric muscular strength in haemophilic subjects. Haemophilia 2001; 7 (06) 582-588
    CrossrefPubMedGoogle Scholar
  • 6 Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. Int J Epidemiol 2011; 40 (05) 1382-1400
    CrossrefPubMedGoogle Scholar
  • 7 Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012; 380 (9838): 219-229
    CrossrefPubMedGoogle Scholar
  • 8 Broderick CR, Herbert RD, Latimer J, Curtin JA. Fitness and quality of life in children with haemophilia. Haemophilia 2010; 16 (01) 118-123
    CrossrefPubMedGoogle Scholar
  • 9 Douma-van Riet DCM, Engelbert RHH, van Genderen FR, Ter Horst-De Ronde MTM, de Goede-Bolder A, Hartman A. Physical fitness in children with haemophilia and the effect of overweight. Haemophilia 2009; 15 (02) 519-527
    CrossrefPubMedGoogle Scholar
  • 10 Versloot O, van Balen EC, Hassan S. et al; Haemophilia in the Netherlands 6 steering committee. Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. Haemophilia 2021; 27 (05) 876-885
    CrossrefPubMedGoogle Scholar
  • 11 Ross C, Goldenberg NA, Hund D, Manco-Johnson MJ. Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis. Pediatrics 2009; 124 (05) 1267-1272
    CrossrefPubMedGoogle Scholar
  • 12 Tiktinsky R, Kenet G, Dvir Z. et al. Physical activity participation and bleeding characteristics in young patients with severe haemophilia. Haemophilia 2009; 15 (03) 695-700
    CrossrefPubMedGoogle Scholar
  • 13 Broderick CR, Herbert RD, Latimer J. et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308 (14) 1452-1459
    CrossrefPubMedGoogle Scholar
  • 14 Holford N. A time to event tutorial for pharmacometricians. CPT Pharmacometrics Syst Pharmacol 2013; 2 (05) e43
    CrossrefPubMedGoogle Scholar
  • 15 Cox EH, Veyrat-Follet C, Beal SL, Fuseau E, Kenkare S, Sheiner LB. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm 1999; 27 (06) 625-644
    CrossrefPubMedGoogle Scholar
  • 16 Abrantes JA, Solms A, Garmann D, Nielsen EI, Jönsson S, Karlsson MO. Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients. Haematologica 2020; 105 (05) 1443-1453
    CrossrefPubMedGoogle Scholar
  • 17 Hajducek DM, Chelle P, Hermans C. et al. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project. Haemophilia 2020; 26 (03) 384-400
    CrossrefPubMedGoogle Scholar
  • 18 Iorio A, Keepanasseril A, Foster G. et al; WAPPS-Hemo co-investigator network. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc 2016; 5 (04) e239
    CrossrefPubMedGoogle Scholar
  • 19 McEneny-King A, Foster G, Iorio A, Edginton AN. Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). JMIR Res Protoc 2016; 5 (04) e232
    CrossrefPubMedGoogle Scholar
  • 20 Yngman G, Bjugård Nyberg H, Nyberg J, Jonsson EN, Karlsson MO. An introduction to the full random effects model. CPT Pharmacometrics Syst Pharmacol 2022; 11 (02) 149-160
    CrossrefPubMedGoogle Scholar
  • 21 Anderson A, Forsyth A. Playing It Safe: Bleeding Disorders, Sports and Exercise. New York, NY: National Hemophilia Foundation; 2017. :1–72
    Google Scholar
  • 22 Beal S, Sheiner L, Boeckmann A, Bauer R. . NONMEM 7.4 Users Guides. Accessed December 5, 2022 at: https://nonmem.iconplc.com/nonmem741
    PubMed
  • 23 Howell C, Scott K, Patel DR. Sports participation recommendations for patients with bleeding disorders. Transl Pediatr 2017; 6 (03) 174-180
    CrossrefPubMedGoogle Scholar
  • 24 Heijnen L. The role of rehabilitation and sports in haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl. 06) 45-51
    CrossrefPubMedGoogle Scholar
  • 25 Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; (Suppl. 77) 3-132
    CrossrefPubMedGoogle Scholar
  • 26 Collins PW, Blanchette VS, Fischer K. et al; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7 (03) 413-420
    CrossrefPubMedGoogle Scholar